In 2008, the National Institute of Health's (NIH) Undiagnosed Disease Program (UDP) was initiated to provide diagnoses for individuals who had long sought one without success. As a result of two international conferences (Rome 2014 and Budapest 2015), the Undiagnosed Diseases Network International (UDNI) was established, modeled in part after the NIH UDP. Undiagnosed diseases are a global health issue, calling for an international scientific and healthcare effort. To meet this demand, the UDNI has built a consensus framework of principles, best practices and governance; the Board of Directors reflects its international character, as it includes experts from Australia, Canada, Hungary, Italy, Japan and the USA. The UDNI involves centers with internationally recognized expertise, and its scientific resources and know-how aim to fill the knowledge gaps that impede diagnosis. Consequently, the UDNI fosters the translation of research into medical practice. Active patient involvement is critical; the Patient Advisory Group is expected to play an increasing role in UDNI activities. All information for physicians and patients will be available at the UDNI website.
In 2008, the NIH Undiagnosed Disease Program (UDP), through the efforts of the National Human Genome Research Institute, the NIH Clinical Center, the Office of Rare Diseases Research, and other NIH research institutes and centers, arose to address an unmet need, to provide a diagnosis for individuals who had long sought one without success. This program evaluates patients for whom medicine has failed to provide a diagnosis. Such patients have spent years accumulating large amounts of medical records and test results, often at great emotional and financial cost. A second, critical goal was to obtain insights into novel disease mechanisms and pathways [1] . In 2013, the Common Fund of the United States' National Institutes of Health (NIH) granted 7 years of support to establish a nationwide Undiagnosed Diseases Network (UDN), consisting of a coordinating center, 7 clinical sites (including the NIH UDP), two sequencing cores, a metabolomics core, a model systems core, and a gene function core. The NIH UDP continues to thoroughly evaluate 120-150 patients per year at the NIH Clinical Center, and the other 6 clinical sites began seeing their first patients in August 2015. The NIH UDN is committed to sharing best practices, genomic, phenotypic and functional data, and expertise among its sites. This is accomplished through use of a common Institutional Review Board (located at the National Human Genome Research Institute) and a consent that allows for sharing of personally identifiable data and specimens among the centers. In addition, de-identified data are shared with qualified collaborators outside of the Network [2, 3] . . In attendance were representatives of 18 countries and 4 continents, and a firm resolve to improve the situation emanated from those meetings. In these international meetings, participants decided to establish the Undiagnosed Diseases Network International (UDNI), modeled in part after the NIH UDN. The objectives of the NIH UDN are to: 1) improve the level of diagnosis and care for patients with undiagnosed diseases through the development of common protocols designed by a community of investigators; 2) facilitate research into the etiology of undiagnosed diseases, by collecting and sharing standardized, high-quality clinical and laboratory data including genotyping, phenotyping, and documentation of environmental exposures; and 3) create an integrated and collaborative research community across multiple clinical sites and among laboratory and clinical investigators prepared to investigate the pathophysiology of these new and rare diseases and share this understanding to identify improved options for optimal patient management. The oncoming UDNI meeting will be in Vienna on February 18, 2016. [6, 7] . Patient phenotypes should be expressed using a standard ontology system in order to build up a highly integrated database [8, 9] . 4. Next-generation sequencing and other -omics analyses (e.g., proteomics, glycomics, lipidomics) should be performed on enrolled families/patients(trios or quartets when possible), and analyzed with some uniformity and according to state-of-the-art protocols. New tools will be applied in some cases, including when a non-genetic undiagnosed disease (e.g., rare infections or poisonings) is suspected. Return of results will conform to site-specific consents. 5. The -omics and phenotypic data should be shared among members of the UDNI. 6. Functional studies should be performed to substantiate causal relationships between a candidate gene and the phenotype and address novel therapies.
Principles

A C C E P T E D M A N U S C R I P T
Practices
The UDNI will adhere to the following best practices. 1. Applications will be specific to member sites, but should include core information described in Appendix A. 2. Clinical site evaluations will be comprehensive and include clinical and basic research approaches, including specimen collection for future studies, as described in Appendix B. 3. A list of clinical experts will be created for advice and referral both within the UDNI and outside of it. 4. A list of basic research topic experts will be compiled to serve as a potential collaborator pool; de-identified cases can be shared with these authorities if they have variants in genes within a particular basic researcher's area of expertise. 5. The UDNI will maintain a website with information for physicians and patients [5] . 6. The NIH UDN will make available its Manual of Operations to the UDNI. Table 1 lists basic principles and their implementation in the NIH UDN. The UDNI is expected to operate under the same principles with similar approaches to implementation.
Implementation of Principles and Practices
Governance
The UDNI will be organized as a consortium with membership and committees. Funding for the UDNI database will be requested from the NIH Common Fund, which supports the NIH UDN. The UDNI website is provided by the Istituto Superiore di Sanità. Members of the UDNI will seek their own funding for their clinical/sequencing/research sites.
The UDNI principles, actions and governance are intended to address several priority health issues. Firstly, undiagnosed diseases are a global health problem, so undiagnosed diseases call for an international framework of scientific co-operation and a consistent transnational healthcare approach. Second, undiagnosed diseases require standards of the highest quality; UDNI involves centers with internationally recognized expertise, robust scientific resources, and specialized experience directed toward filling the knowledge gaps that delay diagnosis. Consequently, the UDNI fosters the translation of research into medical practice. Finally, active patient involvement is crucial; the Patient Advisory Group is expected to play an increasing role in UDNI activities. Generally, patients' participation and experiences contribute to improved health care, and this holds true particularly for patients with undiagnosed diseases that require specialized, coordinated efforts.
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